Clinical Research
Acute Infarction
Prognostic Value of Mid-Regional Pro-Adrenomedullin Levels Taken on Admission and Discharge in Non–ST-Elevation Myocardial Infarction: The LAMP (Leicester Acute Myocardial Infarction Peptide) II Study

https://doi.org/10.1016/j.jacc.2010.01.060Get rights and content
Under an Elsevier user license
open archive

Objectives

The purpose of this study was to assess the prognostic value of admission and discharge mid-regional pro-adrenomedullin (sAM) levels in non–ST-elevation myocardial infarction (MI) and identify values to aid clinical decision making. N-terminal pro–B-type natriuretic peptide and GRACE (Global Registry of Acute Coronary Events) score were used as comparators.

Background

sAM is a stable precursor of adrenomedullin.

Methods

We measured plasma sAM on admission and discharge in 745 non–ST-elevation MI patients (514 men, median age 70.0 ± 12.7 years). The primary end point was a composite of death, heart failure, hospitalization, and recurrent acute MI over mean follow-up of 760 days (range 150 to 2,837 days), with each event assessed individually as secondary end points.

Results

During follow-up, 120 (16.1%) patients died, and there were 65 (8.7%) hospitalizations for heart failure and 77 (10.3%) recurrent acute MIs. Both admission and discharge levels were increased (median 0.81 nmol/l [range 0.06 to 5.75 nmol/l] and 0.76 nmol/l [range 0.25 to 6.95 nmol/l], respectively) compared with established normal ranges. Multivariate adjusted Cox regression models revealed that both were associated with the primary end point (hazard ratio: 9.75 on admission and 7.54 on discharge; both p < 0.001). Admission sAM was particularly associated with early (<30 days) mortality (c-statistic = 0.90, p < 0.001), and when compared with N-terminal pro–B-type natriuretic peptide and GRACE score, it was the only independent predictor of this end point. Admission sAM >1.11 nmol/l identified those at highest risk of death (p < 0.001). Patients with above-median admission sAM may benefit from revascularization.

Conclusions

sAM level is prognostic for death or heart failure. Admission levels are a strong predictor of early mortality and, when >1.11 nmol/l, complements the GRACE score to improve risk stratification.

Key Words

adrenomedullin
Global Registry of Acute Coronary Events score
myocardial infarction
N-terminal pro–B-type natriuretic peptide
prognosis

Abbreviations and Acronyms

ACS
acute coronary syndrome
AM
adrenomedullin
AMI
acute myocardial infarction
BNP
B-type natriuretic peptide
eGFR
estimated glomerular filtration rate
HF
heart failure
HR
hazard ratio
MACE
major adverse cardiac event(s)
MI
myocardial infarction
NRI
net reclassification improvement
NSTEMI
non–ST-segment elevation myocardial infarction
NT-proBNP
N-terminal pro–B-type natriuretic peptide
ROC
receiver-operator characteristic
sAM
mid-regional pro-adrenomedullin abbreviated to surrogate for adrenomedullin
STEMI
ST-segment elevation myocardial infarction

Cited by (0)

Drs. Dhillon, Khan, and Narayan were supported by British Heart Foundation Junior Research Fellowships(grant numbers FS/03/028/15486, FS/03/028/15486, and FS/09/040, respectively). Dr. Ng was supported by the Leicester National Institute for Health Research Cardiovascular Biomedical Research Unitand has submitted patent applications on behalf of the University of Leicester on biomarkers of cardiovascular disease. Drs. Struck and Morgenthaler are employees of BRAHMS AG, a mid-sized company based in Hennigsdorf, Germany that commercializes immunoassays and has developed the Midregional Pro-Adrenomedullin assay, for which it owns the patent rights. Dr. Bergmann holds ownership in and is a member of the board of directors of BRAHMS AG.